BRPI0517305A - formulação liofilizada estabilizada para derivados de cefalosporina - Google Patents

formulação liofilizada estabilizada para derivados de cefalosporina

Info

Publication number
BRPI0517305A
BRPI0517305A BRPI0517305-1A BRPI0517305A BRPI0517305A BR PI0517305 A BRPI0517305 A BR PI0517305A BR PI0517305 A BRPI0517305 A BR PI0517305A BR PI0517305 A BRPI0517305 A BR PI0517305A
Authority
BR
Brazil
Prior art keywords
lyophilized formulation
cephalosporin derivatives
stabilized lyophilized
derivatives
formulation
Prior art date
Application number
BRPI0517305-1A
Other languages
English (en)
Inventor
Markus Heubes
Wilhelm Scigalla
Original Assignee
Basilea Pharmaceutica Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basilea Pharmaceutica Ag filed Critical Basilea Pharmaceutica Ag
Publication of BRPI0517305A publication Critical patent/BRPI0517305A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

FORMULAçãO LIOFILIZADA ESTABILIZADA PARA DERIVADOS DE CEFALOSPORINA. A presente invenção refere-se a uma formulação liofihizada para derivados de cefalosporina com maior estabilidade, a uma solução para sua obtenção e a um método para a preparação dessa formulação, assim como ao uso de certos compostos para a estabilização de derivados de cefalosporina em formulações liofilizadas. Os compostos preferencialmente usados como estabilizadores de acordo com a invenção são o manitol, trealose e PVP.
BRPI0517305-1A 2004-11-10 2005-11-10 formulação liofilizada estabilizada para derivados de cefalosporina BRPI0517305A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04405690A EP1656930A1 (en) 2004-11-10 2004-11-10 Stabilized freeze-dried formulation for cephalosporin derivatives
PCT/CH2005/000665 WO2006050631A1 (en) 2004-11-10 2005-11-10 Stabilized freeze-dried formulation for cephalosporin derivatives

Publications (1)

Publication Number Publication Date
BRPI0517305A true BRPI0517305A (pt) 2008-10-07

Family

ID=34932353

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0517305-1A BRPI0517305A (pt) 2004-11-10 2005-11-10 formulação liofilizada estabilizada para derivados de cefalosporina

Country Status (24)

Country Link
US (2) US20080032962A1 (pt)
EP (3) EP1656930A1 (pt)
JP (1) JP2008519775A (pt)
KR (1) KR20070084150A (pt)
CN (1) CN101056623B (pt)
AR (1) AR052233A1 (pt)
AT (1) ATE468844T1 (pt)
AU (1) AU2005304252B2 (pt)
BR (1) BRPI0517305A (pt)
CA (1) CA2585296A1 (pt)
CY (1) CY1110731T1 (pt)
DE (1) DE602005021530D1 (pt)
DK (1) DK1809253T3 (pt)
ES (1) ES2342833T3 (pt)
HR (1) HRP20100364T1 (pt)
MX (1) MX2007005677A (pt)
MY (1) MY142648A (pt)
PL (1) PL1809253T3 (pt)
PT (1) PT1809253E (pt)
RS (1) RS51380B (pt)
SI (1) SI1809253T1 (pt)
TW (1) TW200630118A (pt)
WO (1) WO2006050631A1 (pt)
ZA (1) ZA200703760B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080103121A1 (en) * 2006-10-30 2008-05-01 Gole Dilip J Cephalosporin derivative formulation
US20100280064A1 (en) * 2006-12-07 2010-11-04 Tomoyuki Watanabe Pharmaceutical composition having improved storage stability
TWI482641B (zh) 2006-12-07 2015-05-01 Daiichi Sankyo Co Ltd 含有低取代度羥丙基纖維素之醫藥組成物
TW200940552A (en) * 2008-03-04 2009-10-01 Elan Pharm Inc Stable liquid formulations of anti-infective agents and adjusted anti-infective agent dosing regimens
EP2106788A1 (en) * 2008-04-04 2009-10-07 Ipsen Pharma Liquid and freeze dried formulations
EP2236520A1 (en) * 2009-03-31 2010-10-06 Leukocare Ag Stabilizing composition for immobilized biomolecules
US20130089638A1 (en) 2011-10-11 2013-04-11 Mead Johnson Nutrition Company Compositions Comprising Maltotriose And Methods Of Using Same To Inhibit Damage Caused By Dehydration Processes
CN102716075B (zh) * 2012-07-03 2013-08-21 哈药集团制药总厂 一种含有头孢唑肟钠的药物组合物
CN102727451B (zh) * 2012-07-03 2013-07-03 哈药集团制药总厂 一种含有头孢美唑钠的药物组合物
CN103271877A (zh) * 2012-12-18 2013-09-04 张宏民 一种头孢西丁钠注射剂及其制备方法
BR112015022716A2 (pt) 2013-03-13 2017-07-18 Theravance Biopharma Antibiotics Ip Llc sais de cloridrato de um composto antibiótico
CN110507619B (zh) * 2019-08-19 2021-12-03 湖北美林药业有限公司 注射用头孢哌酮钠及其制备方法
EP4316509A4 (en) * 2021-03-25 2025-11-26 House Foods Group Inc TEAR FACTOR GENERATION KIT
WO2022202994A1 (ja) * 2021-03-25 2022-09-29 ハウス食品グループ本社株式会社 乾燥ｐｒｅｎｃｓｏ組成物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2690009B2 (ja) * 1986-07-10 1997-12-10 エーザイ 株式会社 セフアロスポリン注射剤
DE3801179A1 (de) * 1988-01-18 1989-07-27 Hoechst Ag Stabilisierung von cephalosporinderivaten durch trocknung mit einem stabilisator sowie stabile zubereitungsformen mit cephalosporinderivaten
ES2059947T3 (es) * 1989-09-30 1994-11-16 Eisai Co Ltd Preparados inyectables que contienen cefalosporina y utilizacion de los mismos.
JPH0459730A (ja) * 1990-06-26 1992-02-26 Dai Ichi Seiyaku Co Ltd セフェム系抗生物質含有凍結乾燥製剤
ATE231871T1 (de) * 1998-06-15 2003-02-15 Basilea Pharmaceutica Ag 3-(2-oxo-(1,3')bipyrrolidinyl-3-yliden-methyl)- cephemderivate
US7378408B2 (en) * 2001-11-30 2008-05-27 Pfizer Inc. Methods of treatment and formulations of cephalosporin
WO2004000323A1 (ja) * 2002-06-21 2003-12-31 Shionogi & Co., Ltd. セフェム化合物の注射用医薬組成物

Also Published As

Publication number Publication date
ATE468844T1 (de) 2010-06-15
US20100160278A1 (en) 2010-06-24
DE602005021530D1 (de) 2010-07-08
WO2006050631A1 (en) 2006-05-18
TW200630118A (en) 2006-09-01
AU2005304252A1 (en) 2006-05-18
PL1809253T3 (pl) 2010-10-29
EP1656930A1 (en) 2006-05-17
EP2210592A2 (en) 2010-07-28
HRP20100364T1 (hr) 2010-07-31
RS51380B (sr) 2011-02-28
CY1110731T1 (el) 2015-06-10
DK1809253T3 (da) 2010-07-12
CA2585296A1 (en) 2006-05-18
SI1809253T1 (sl) 2010-09-30
ES2342833T3 (es) 2010-07-15
KR20070084150A (ko) 2007-08-24
JP2008519775A (ja) 2008-06-12
AR052233A1 (es) 2007-03-07
MY142648A (en) 2010-12-15
PT1809253E (pt) 2010-09-03
CN101056623A (zh) 2007-10-17
AU2005304252B2 (en) 2009-07-16
CN101056623B (zh) 2011-04-06
ZA200703760B (en) 2008-06-25
US20080032962A1 (en) 2008-02-07
EP1809253A1 (en) 2007-07-25
EP2210592A3 (en) 2011-12-14
EP1809253B1 (en) 2010-05-26
MX2007005677A (es) 2007-07-20

Similar Documents

Publication Publication Date Title
UY31209A1 (es) Uso de homo y copolimeros para la estabilización de formulaciones de principios activos
ATE405253T1 (de) Gelzusammensetzung mit geladenen polymeren
NZ596367A (en) Lyophilized therapeutic peptibody formulations
CY1110731T1 (el) Σταθεροποιημενο λυοφιλιωμενο παρασκευασμα για παραγωγα κεφαλοσπορινης
BRPI0511441B8 (pt) composições contendo uma partícula de glucano oca ou partícula de parede celular encapsulando um componente de terpeno, métodos de fabricação e uso das mesmas
EA200870264A1 (ru) Композиция антител
BRPI0615292A8 (pt) composições e métodos para preparação de fármacos de má solubilidade em água com estabilidade aumentada
NO20064584L (no) Tetrahydropyridoindolderivater
WO2010056991A8 (en) Vaccine formulations and uses thereof
CL2009000200A1 (es) Compuestos derivados de 2,7-naftiridinas-1-ona, mediadores de syk; composicion farmaceutica; y uso en el tratamiento de una enfermedad inflamatoria, respiratoria, proliferativa celular o autoinmune.
MX387269B (es) Formulaciones de factor ix liofilizadas.
CY1114148T1 (el) Γεφυρωμενες δικυκλικες αρυλο- και γεφυρωμενες δικυκλικες etepoapyλo-υποκατεστημενες τριαζολες χρησιμες ως αναστολεις toy axl
BR112017009405A2 (pt) composições antibióticas.
WO2015120231A3 (en) Stable peptide formulations and methods for preparation
BRPI0615265A8 (pt) composições compreendendo agentes farmacêuticos pouco hidrossoluíveis e agentes antimicrobianos
BR112012016021A8 (pt) Formulações estáveis para liofilização de partículas terapêuticas
ATE470443T1 (de) Indol-1-yl-essigsäurederivate
EA200901365A1 (ru) Стабилизированная фармацевтическая композиция, содержащая прегабалин
AR046690A1 (es) Composiciones de adn estabilizado para recubrir microproyecciones
BRPI0519312A2 (pt) composiÇço biologicamente ativa, composiÇço de liofilizaÇço, mÉtodo para a liofilizaÇço de virossomas utilizando as composiÇÕes, liofilizado de virossoma, mÉtodo para reconstituiÇço de um liofilizado de virossoma, uso de qualquer uma das composiÇÕes, kit, e, uso de um derivado de colesterila catiânico
TN2011000261A1 (en) Octreotide depot formulation with constantly high exposure levels
WO2011069037A3 (en) Stabilization and storage of biological pharmaceutical compositions
EA201991023A1 (ru) Фармацевтическая композиция для парентерального введения, содержащая карглумовую кислоту
SA520420261B1 (ar) تركيبات إرنوماب واستخداماتها
DE60009926D1 (de) Stabilisierung von gefriergetrocknetem kuchen

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2260 DE 29/04/2014.